Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $58.83 Consensus Price Target from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $60.60.

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Citigroup raised their target price on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. BTIG Research increased their price target on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Stephens reiterated an “overweight” rating and issued a $68.00 price target on shares of Establishment Labs in a report on Wednesday, August 7th.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in shares of Establishment Labs by 32,968.7% during the first quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock worth $4,949,000 after purchasing an additional 96,928 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Establishment Labs in the first quarter valued at $4,185,000. Divisadero Street Capital Management LP acquired a new stake in shares of Establishment Labs during the 2nd quarter worth about $5,829,000. Principal Financial Group Inc. purchased a new position in Establishment Labs during the second quarter worth about $593,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Establishment Labs in the 1st quarter valued at approximately $631,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $37.51 on Friday. The stock’s 50 day simple moving average is $43.32 and its two-hundred day simple moving average is $45.75. Establishment Labs has a 1 year low of $21.25 and a 1 year high of $60.12. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -14.36 and a beta of 1.20. The company has a debt-to-equity ratio of 4.30, a current ratio of 4.44 and a quick ratio of 2.91.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.